Canadian Pharmacy Blog

A difficult topic has being discussed by the Committee of experts. The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) declared that Zyprexa (Olanzapine) drug is effective and safe in treating of schizophrenia or manic or mixed episodes associated with bipolar I disorder in patients aged 13-17 years old.

John Hayes, M.D., vice president of Lilly Research Laboratories suggested that the Committee vote is an important step in providing help and hope to the many young patients having severe mental illness.

In the review of the supplemental New Drug Applications FDA will take into consideration the panel’s recommendations and the advice of its Advisory Committees when deciding whether to approve new indications.

[Read Full Article]

New data received by Corcept Therapeutics (NASDAQ: CORT) demonstrated that adding CORLUX to Risperdal (Risperidone) treatment mitigates the weight gain associated with Risperdal drug.

Generic Risperdal is a well-known kind of schizophrenia medication, that is effective for the treatment of schizophrenia disease and bipolar disorder.

CORLUX, Corcept’s late-stage GRII receptor antagonist, was investigated in a four-week randomized double-blind controlled study of 75 lean, healthy men (body mass index of 23 or less). The patients were randomized to receive Risperdal plus placebo, Risperdal plus CORLUX or CORLUX plus placebo. All the daily figures of weights were recorded.

[Read Full Article]

Abilify (Aripiprazole) is considered to be an effective antipsychotic medication for treating schizophrenia disease and Bipolar I Disorder. The drug is developed by two partnered companies: Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company.

They announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Abilify drug for filing. Besides, FDA granted a Priority Review to sNDA for the treatment of pediatric patients (10 to 17 years old) suffer from Bipolar I Disorder, manic or mixed episode with or without psychotic features.

[Read Full Article]

It is known that Zyprexa (Olanzapine) drug is effective in treating of schizophrenia, acute mixed and manic episodes of bipolar I disorder. This medicine is widely prescribed for adults in the United States.

However, there are some cases to be cautious taking Olanzapine tablets.

First, this kind of schizophrenia medication is not approved for the treatment of patients with dementia-related psychosis. For example, in elderly patients with dementia-related there was a significantly higher incidence of cerebrovascular adverse events psychosis, besides such pateints are at an increased risk of death.

Second, it has been reported that in patients treated with atypical antipsychotics, including Zyprexa 10 mg appears Hyperglycemia, in some cases associated with ketoacidosis, coma, or death.

[Read Full Article]

Seroquel (Quetiapine) (original formulation) is considered to be a well-known prescribed atypical antipsychotic medicine in the United States. In October 2006 it was approved in the US by the FDA for the treatment of bipolar manic depression. By the way, another form, Quetiapine drug sustained release formulation for the treatment of schizophrenia disease, has not yet been approved and is under review by regulatory authorities around the world.

According to the updated information of AstraZeneca, the clinical trials showed that the once-daily generic Seroquel sustained-release formulation considerably improved symptoms associated with schizophrenia and lessened the time to psychiatric relapse. The results were demonstrated at the European Congress of Psychiatry (ECP) in Madrid.

[Read Full Article]

Taro Iwamoto, Ph.D., Chief Executive Officer, President and Chief Operating Officer, Otsuka Pharmaceutical Development and Commercialization, Inc. stated that they are very pleased to receive expanded indications on the use of Abilify (Aripiprazole) in pediatric patients (aged 10-17) and adolescents.

In fact, The FDA first approved ABILIFY antipsychotic medicine for the treatment of manic and mixed episodes associated with Bipolar I Disorder in adults in September 2004, and as schizophrenia medication for adults in November 2002. In 2007-2008 Abilify drug has received the approval for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in pediatric patients, and for the acute treatment of Schizophrenia in adolescents. And now Abilify medication is indicated for maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features and maintenance treatment of Schizophrenia in adolescents. Moreover, ABILIFY antipsychotic medication is given an indication for adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in pediatric patients. [Read Full Article]

In a class of antipsychotic drugs generic Lexapro is a useful treatment option for treating depression. A new study was conducted and Forest Laboratories, Inc., (NYSE: FRX) today announced the results.

The randomized, double-blinded study involved patients 18-80 years of age with DSM-IV diagnosed MDD as determined by a Montgomery-Asberg Depression Rating Scale (MADRS) score of 26 or greater. The participants were administered to take Lexapro 10mg per day (the dose was increased to 20 mg per day) or Cymbalta antipsychotic medicine 60 mg per day. The period of treatment amounted 8 weeks.

[Read Full Article]